Regeneron (REGN) CFO Christopher Fenimore Exercises Options

What Happened

• Christopher R. Fenimore, EVP Finance and CFO of Regeneron Pharmaceuticals, exercised stock options on Aug 18, 2026. He exercised 6,283 option shares at $381.92 per share (exercise payment ≈ $2,399,603) and, concurrently, 4,599 shares were surrendered/withheld to cover tax and exercise obligations at $813.47 per share (proceeds ≈ $3,741,149). The filing also shows the underlying option units (6,283) converted/cancelled (derivative line at $0). Net shares retained after withholding: 1,684 (6,283 − 4,599).

Key Details

• Transaction date: 2026-08-18 (filed: 2026-08-20; filing appears timely).
• Exercise (code M): 6,283 shares @ $381.92 = $2,399,603 (acquired).
• Tax/exercise withholding (code F): 4,599 shares @ $813.47 = $3,741,149 (disposed).
• Derivative conversion (code M): 6,283 option units disposed @ $0 (reflects cancellation of options upon exercise).
• Net shares retained: 1,684 shares (6,283 acquired − 4,599 withheld).
• Footnotes: F1 — some shares are held in a trust for the reporting person’s spouse (the reporting person and spouse are trustees). F2 — the option award vested in four equal annual installments beginning one year after grant.
• Filing timeliness: Transaction dated Aug 18; Form 4 filed Aug 20 (within the usual 2-business-day window).

Context

• This was an options exercise with shares surrendered to cover taxes/exercise costs (a cashless/withholding-style settlement), not an open-market sell driven by price-taking. Such withholdings are common and often routine for option exercises. No 10% owner or gift transactions are indicated; this is executive-level option activity.